MedPath

High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome

Not Applicable
Completed
Conditions
Polycystic Ovary Syndrome
Registration Number
NCT01919281
Lead Sponsor
Norwegian University of Science and Technology
Brief Summary

The aim is to investigate whether strength training or high intensity interval training is effective in improving insulin sensitivity, cardiovascular outcomes, body composition and reproductive outcomes in women with Polycystic Ovary Syndrome (PCOS).

Few studies have examined the effect of strength training alone on insulin sensitivity, reproductive outcomes and body composition in women with PCOS. Most previous studies on aerobic exercise in PCOS have applied moderate exercise intensity.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
31
Inclusion Criteria
  • Women
  • Age 18-45 years old
  • PCOS
Exclusion Criteria
  • Regular high intensity endurance or strength training (two or more times per week of vigorous exercise).
  • Concurrent treatments (insulin sensitizers or drugs known to affect gonadotropin or ovulation, with a wash out period of 1 months prior to inclusion).
  • On-going pregnancy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
insulin resistance10 weeks

measured with the homeostatic model assessment for insulin resistance (HOMA-IR) method

Secondary Outcome Measures
NameTimeMethod
Body composition10 weeks

Measured as body fat % on an impedance scale and waist circumference

Maximum oxygen uptake10 weeks

Measured during maximum effort exercise test

Endothelial function10 weeks

Flow mediated dilatation of the brachial artery.

Trial Locations

Locations (1)

Department of circulation and medical imaging , NTNU

🇳🇴

Trondheim, Norway

Department of circulation and medical imaging , NTNU
🇳🇴Trondheim, Norway

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.